Screening for lung cancer: What comes next?

Journal of Clinical Oncology

Volumn 33, Issue 33, 2015, Pages 3847-3848

  Peled, Nir ^a   Ilouze, Maya ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BETA CAROTENE; EPIDERMAL GROWTH FACTOR RECEPTOR; RETINOL; SURFACTANT PROTEIN B; PROTEIN PRECURSOR; SPERMINE; SURFACTANT ASSOCIATED PROTEIN; TUMOR MARKER;

ALGORITHM; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; FOLLOW UP; HUMAN; LUNG CANCER; LUNG NODULE; PREDICTIVE VALUE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; BLOOD; EARLY CANCER DIAGNOSIS; FEMALE; LUNG TUMOR; MALE; NON SMALL CELL LUNG CANCER; PROCEDURES;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN PRECURSORS; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; SPERMINE;

EID: 84948454843     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.1713     Document Type: Editorial

References (21)

1. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998-2006, 2014
2. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028, 2015
3. Paz-Ares L, Horn L, Borghaei H, et al: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 33:15s, 2015 (abstr LBA109)
4. Aberle DR, Adams AM, Berg CD, et al: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395-409, 2011
5. Shlomi D, Ben-Avi R, Balmor GR, et al: Screening for lung cancer: Time for large-scale screening by chest computed tomography. Eur Respir J 44:217-238, 2014
6. Kauczor HU, Bonomo L, Gaga M, et al: ESR/ERS white paper on lung cancer screening. Eur Respir J 46:28-39, 2015
7. van Iersel CA, de Koning HJ, Draisma G, et al: Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 120:868-874, 2007
8. Kovalchik SA, Tammemagi M, Berg CD, et al: Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 369:245-254, 2013
9. Marcus MW, Raji OY, and Field JK: Lung cancer screening: Identifying the high risk cohort. J Thorac Dis 7:S156-S162, 2015 (suppl 2)
10. McWilliams A, Tammemagi MC, Mayo JR, et al: Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 369:910-919, 2013
11. National Cancer Institute: Early Detection Research Network. http://edrn.nci.nih.gov/
12. Pepe MS, Etzioni R, Feng Z, et al: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054-1061, 2001
13. Wikoff WR, Hanash S, DeFelice B, et al: Diacetylspermine is a novel prediagnostic serum biomarker for non-small-cell lung cancer and has additive performance with pro-surfactant protein B. J Clin Oncol 33:3880-3886, 2015
14. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996
15. Sozzi G, Boeri M, Rossi M, et al: Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: A correlative MILD trial study. J Clin Oncol 32:768-773, 2014
16. Jett JR, Peek LJ, Fredericks L, et al: Audit of the autoantibody test, EarlyCDT-lung, in 1600 patients: An evaluation of its performance in routine clinical practice. Lung Cancer 83:51-55, 2014
17. Ajona D, Razquin C, Pastor MD, et al: Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer. PLoS One 10:e0119878, 2015
18. Bianchi F, Nicassio F, Marzi M, et al: A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3:495-503, 2011
19. Sozzi G, Boeri M: Potential biomarkers for lung cancer screening. Transl Lung Cancer Res 3:139-148, 2014
20. Hensing TA, Salgia R: Molecular biomarkers for future screening of lung cancer. J Surg Oncol 108:327-333, 2013
21. Kulpa J, Wójcik E, Reinfuss M, et al: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48:1931-1937, 2002